Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Basic Sciences

Human T-Lymphocytes Targeted against an Established Human Ovarian Carcinoma with a Bispecific F(ab′)2 Antibody Prolong Host Survival in a Murine Xenograft Model

Delia Mezzanzanica, Maria A. Garrido, Donald S. Neblock, Peter E. Daddona, Sarah M. Andrew, Vincent R. Zurawski Jr., David M. Segal and John R. Wunderlich
Delia Mezzanzanica
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria A. Garrido
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald S. Neblock
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter E. Daddona
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah M. Andrew
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent R. Zurawski Jr.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David M. Segal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John R. Wunderlich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published October 1991
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

A bispecific F(ab′)2 fragment with anti-CD3 and antitumor specificity was used to target activated human peripheral blood lymphocytes (PBL) against OVCAR-3 human ovarian carcinoma cells growing i.p. in athymic mice. Mice were given injections of OVCAR-3 cells on day 0 and treated with i.p. injections of activated PBL coated with the [anti-CD3 (TR66) × antitumor (MOv18)] bispecific F(ab′)2 on day 4, using an approximate effector:target ratio of 1:1. Treatment was evaluated for the ability either to block tumor growth at 15 days or to prolong survival of tumor-bearing mice. After 15 days, the incidence of mice with tumor growth was 20% among those given PBL coated with bispecific F(ab′)2, whereas the incidence among mice untreated or treated with PBL alone or PBL with either parental antibody ranged from 80 to 94%. The mean survival time of tumor-bearing mice treated with PBL and bispecific F(ab′)2 was 104 days, which was 3.5 times that of untreated mice and twice that of mice given PBL alone or PBL with either parental antibody. These results provide support for the concept that treatment of ovarian cancer patients with targeted T-cells could prove beneficial.

Footnotes

  • ↵2 To whom requests for reprints should be addressed.

  • Received May 8, 1991.
  • Accepted August 6, 1991.
  • ©1991 American Association for Cancer Research.
PreviousNext
Back to top
October 1991
Volume 51, Issue 20
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Human T-Lymphocytes Targeted against an Established Human Ovarian Carcinoma with a Bispecific F(ab′)2 Antibody Prolong Host Survival in a Murine Xenograft Model
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Human T-Lymphocytes Targeted against an Established Human Ovarian Carcinoma with a Bispecific F(ab′)2 Antibody Prolong Host Survival in a Murine Xenograft Model
Delia Mezzanzanica, Maria A. Garrido, Donald S. Neblock, Peter E. Daddona, Sarah M. Andrew, Vincent R. Zurawski Jr., David M. Segal and John R. Wunderlich
Cancer Res October 15 1991 (51) (20) 5716-5721;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Human T-Lymphocytes Targeted against an Established Human Ovarian Carcinoma with a Bispecific F(ab′)2 Antibody Prolong Host Survival in a Murine Xenograft Model
Delia Mezzanzanica, Maria A. Garrido, Donald S. Neblock, Peter E. Daddona, Sarah M. Andrew, Vincent R. Zurawski Jr., David M. Segal and John R. Wunderlich
Cancer Res October 15 1991 (51) (20) 5716-5721;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Basic Sciences

  • c-myc Gene-induced Alterations in Protein Kinase C Expression: A Possible Mechanism Facilitating myc-ras Gene Complementation
  • Identification of a Novel Tumor-associated Mr 110,000 Gene Product in Human Gastric Carcinoma Cells That Is Immunologically Related to Carcinoembryonic Antigen
  • Induction of Tissue-type Plasminogen Activator by Ionizing Radiation in Human Malignant Melanoma Cells
Show more Basic Sciences

Immunology

  • Abstract 6666: Evaluation of the complexity of the immune response to CMP-001, a TLR9 agonist
  • Abstract 6596: High affinity chimeric antigen receptors with cross reactivity to clinically relevant EGFR mutated proteins
  • Abstract 6599: Screening and characterization of AlloCAR T targeting DLL3 for the treatment of small cell lung cancer
Show more Immunology

Articles

  • Abstract 6666: Evaluation of the complexity of the immune response to CMP-001, a TLR9 agonist
  • Abstract 6596: High affinity chimeric antigen receptors with cross reactivity to clinically relevant EGFR mutated proteins
  • Abstract 6599: Screening and characterization of AlloCAR T targeting DLL3 for the treatment of small cell lung cancer
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement